In this study, we performed an in vivo CRISPR screen in a murine tumor model to systematically explore the tumor-specific genes involved in regulating responses to ICT and identified Ptdss1, which, when knocked out in cancer, can alter cancer cell fitness under selective pressure of anti–PD-1 therapy. Here, PTDSS1 is linked to neoplasm.